iShares Biotechnology ETF $IBB Holdings Boosted by Erste Asset Management GmbH

Posted by ABMN Staff on Jun 9th, 2026

Erste Asset Management GmbH boosted its holdings in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 58.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,330 shares of the financial services provider’s stock after acquiring an additional 37,860 shares during the period. Erste Asset Management GmbH owned about 0.21% of iShares Biotechnology ETF worth $17,270,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Basepoint Wealth LLC bought a new position in iShares Biotechnology ETF in the fourth quarter worth about $26,000. Cary Street Partners Financial LLC bought a new position in iShares Biotechnology ETF in the fourth quarter worth about $29,000. Darwin Wealth Management LLC bought a new position in iShares Biotechnology ETF in the second quarter worth about $25,000. Cornerstone Planning Group LLC bought a new position in iShares Biotechnology ETF in the fourth quarter worth about $35,000. Finally, Copia Wealth Management bought a new position in iShares Biotechnology ETF in the fourth quarter worth about $34,000. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Price Performance

Shares of NASDAQ IBB opened at $166.92 on Tuesday. The firm’s 50-day moving average price is $169.98 and its two-hundred day moving average price is $170.59. iShares Biotechnology ETF has a 52-week low of $123.61 and a 52-week high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 20th. Shareholders of record on Tuesday, March 17th were paid a $0.1218 dividend. The ex-dividend date was Tuesday, March 17th. This represents a $0.49 annualized dividend and a dividend yield of 0.3%.

iShares Biotechnology ETF Company Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.